CYN
Cyngn Inc.
Software - Application
Market Cap$14M
5Y Perf.-100.0%
Build Your Comparison
Side-by-side financial analysisCYN
RBOT
Try popular comparisons:
Stock Comparison
CYN vs RBOT
Revenue, margins, valuation, and 5-year total return — side by side.
RBOT
Vicarious Surgical Inc.
Medical - Devices
Market Cap$3M
5Y Perf.-99.9%
CYN vs RBOT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  CYN |  RBOT |
|---|---|---|
| Industry | Software - Application | Medical - Devices |
| Market Cap | $14M | $3M |
| Revenue (TTM) | $276K | $0.00 |
| Net Income (TTM) | $-26M | $-42M |
| Gross Margin | 34.4% | — |
| Operating Margin | -99.2% | — |
| Total Debt | $7M | $8M |
| Cash & Equiv. | $990K | $3M |
CYN vs RBOT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CYN
RBOT
| Stock | Oct 21 | Jun 26 | Return |
|---|---|---|---|
| Cyngn Inc. (CYN) | 100 | 0.0 | -100.0% |
| Vicarious Surgical … (RBOT) | 100 | 0.1 | -99.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CYN vs RBOT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CYN leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Vicarious Surgical Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇CYN emerged as the overall leader. Track its performance:
CYN
Cyngn Inc.
The Income Pick
CYN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 2.18
- Rev growth -40.5%, EPS growth 76.6%, 3Y rev CAGR -5.8%
- Lower volatility, beta 2.18, Low D/E 17.6%, current ratio 8.29x
Best for: income & stability and growth exposure
RBOT
Vicarious Surgical Inc.
The Long-Run Compounder
RBOT is the clearest fit if your priority is long-term compounding.
- -99.8% 10Y total return vs CYN's -100.0%
- 31.5% revenue growth vs CYN's -40.5%
- 5.0% margin vs CYN's -94.2%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  RBOT | 31.5% revenue growth vs CYN's -40.5% |
| Quality / Margins | RBOT | 5.0% margin vs CYN's -94.2% |
| Stability / Safety |  CYN | Beta 2.18 vs RBOT's 2.42, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CYN | -72.6% vs RBOT's -94.1% |
| Efficiency (ROA) | CYN | -48.1% ROA vs RBOT's -164.5%, ROIC -117.2% vs -116.2% |
CYN vs RBOT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCYNLAGGINGRBOT
RBOTVicarious Surgical In…
1leads
CYNCyngn Inc.
3leads
6 Total Categories
CATEGORYLEADERvs RBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CYN1/1
Valuation MetricsMultiples, price ratios, and targets
CYN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CYN6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RBOT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CYN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CYN and RBOT operate at a comparable scale, with $276,397 and $0 in trailing revenue.
| Metric | CYNCyngn Inc. | RBOTVicarious Surgica… |
|---|---|---|
| RevenueTrailing 12 months | $276,397 | $0 |
| EBITDAEarnings before interest/tax | -$26M | -$41M |
| Net IncomeAfter-tax profit | -$26M | -$42M |
| Free Cash FlowCash after capex | -$27M | -$40M |
| Gross MarginGross profit ÷ Revenue | +34.4% | — |
| Operating MarginEBIT ÷ Revenue | -99.2% | — |
| Net MarginNet income ÷ Revenue | -94.2% | — |
| FCF MarginFCF ÷ Revenue | -97.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +121.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +91.1% | +58.1% |
CYN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CYN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | CYNCyngn Inc. | RBOTVicarious Surgica… |
|---|---|---|
| Market CapShares × price | $14M | $3M |
| Enterprise ValueMkt cap + debt − cash | $19M | $9M |
| Trailing P/EPrice ÷ TTM EPS | -0.24x | -0.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 62.34x | — |
| Price / BookPrice ÷ Book value/share | 0.15x | 0.31x |
| Price / FCFMarket cap ÷ FCF | — | — |
CYN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
CYN leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CYN delivers a -59.6% return on equity — every $100 of shareholder capital generates $-60 in annual profit, vs $-3 for RBOT. CYN carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), CYN scores 3/9 vs RBOT's 1/9, reflecting mixed financial health.
| Metric | CYNCyngn Inc. | RBOTVicarious Surgica… |
|---|---|---|
| ROE (TTM)Return on equity | -59.6% | -3.3% |
| ROA (TTM)Return on assets | -48.1% | -164.5% |
| ROICReturn on invested capital | -117.2% | -116.2% |
| ROCEReturn on capital employed | -71.5% | -134.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | 0.18x | 0.79x |
| Net DebtTotal debt minus cash | $6M | $5M |
| Cash & Equiv.Liquid assets | $990,023 | $3M |
| Total DebtShort + long-term debt | $7M | $8M |
| Interest CoverageEBIT ÷ Interest expense | -59.79x | — |
CYN leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RBOT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RBOT five years ago would be worth $17 today (with dividends reinvested), compared to $0 for CYN. Over the past 12 months, CYN leads with a -72.6% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors RBOT at -80.0% vs CYN's -95.5% — a key indicator of consistent wealth creation.
| Metric | CYNCyngn Inc. | RBOTVicarious Surgica… |
|---|---|---|
| YTD ReturnYear-to-date | -54.9% | -79.8% |
| 1-Year ReturnPast 12 months | -72.6% | -94.1% |
| 3-Year ReturnCumulative with dividends | -100.0% | -99.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -99.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.8% |
| CAGR (3Y)Annualised 3-year return | -95.5% | -80.0% |
RBOT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CYN and RBOT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CYN is the less volatile stock with a 2.18 beta — it tends to amplify market swings less than RBOT's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | CYNCyngn Inc. | RBOTVicarious Surgica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.18x | 2.42x |
| 52-Week HighHighest price in past year | $41.54 | $13.75 |
| 52-Week LowLowest price in past year | $1.22 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +3.0% | +3.7% |
| RSI (14)Momentum oscillator 0–100 | 36.0 | 36.5 |
| Avg Volume (50D)Average daily shares traded | 277K | 14K |
Evenly matched — CYN and RBOT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | CYNCyngn Inc. | RBOTVicarious Surgica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CYN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). RBOT leads in 1 (Total Returns). 1 tied.
Best OverallCyngn Inc. (CYN)Leads 3 of 6 categories
Loading custom metrics...
CYN vs RBOT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — CYN or RBOT?
Over the past 5 years, Vicarious Surgical Inc.
(RBOT) delivered a total return of -99. 8%, compared to -100. 0% for Cyngn Inc. (CYN). Over 10 years, the gap is even starker: RBOT returned -99. 8% versus CYN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — CYN or RBOT?
By beta (market sensitivity over 5 years), Cyngn Inc.
(CYN) is the lower-risk stock at 2. 18β versus Vicarious Surgical Inc. 's 2. 42β — meaning RBOT is approximately 11% more volatile than CYN relative to the S&P 500. On balance sheet safety, Cyngn Inc. (CYN) carries a lower debt/equity ratio of 18% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — CYN or RBOT?
On earnings-per-share growth, the picture is similar: Cyngn Inc.
grew EPS 76. 6% year-over-year, compared to 21. 2% for Vicarious Surgical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — CYN or RBOT?
Vicarious Surgical Inc.
(RBOT) is the more profitable company, earning 0. 0% net margin versus -107. 2% for Cyngn Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RBOT leads at 0. 0% versus -117. 3% for CYN. At the gross margin level — before operating expenses — CYN leads at 38. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CYN or RBOT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CYN or RBOT better for a retirement portfolio?
For long-horizon retirement investors, Vicarious Surgical Inc.
(RBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cyngn Inc. (CYN) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RBOT: -99. 8%, CYN: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CYN and RBOT?
These companies operate in different sectors (CYN (Technology) and RBOT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.